|Bid||0.8611 x 1100|
|Ask||0.8639 x 800|
|Day's range||0.8000 - 0.9135|
|52-week range||0.8000 - 4.0000|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Earnings date||08 May 2023 - 12 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.33|
Good afternoon, and thank you for joining the Inovio 2022 fourth quarter and full year financial results conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO and Dr. Michael Sumner, chief medical officer; and Mr. Today's call will review our corporate and financial information for the quarter and year ended December 31st, 2022, as well as provide an update on our efforts to develop our DNA medicines platform.
Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) shareholders should be happy to see the share price up 11% in the last...